Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Status:
Terminated
Trial end date:
2021-03-05
Target enrollment:
Participant gender:
Summary
Single center, single arm phase Ib trial to test the feasibility and safety of Tumor-
Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) combined with low-dose irradiation in
patients with advanced or metastatic solid tumors. The trial is based on lymphodepleting
chemotherapy followed by low dose irradiation (LDI), and then ACT utilizing ex vivo expanded
TILs in combination with high dose IL-2 (optional, depending on patient's tolerance). LDI
will be administered once to metastatic lesions using tomotherapy.